Results of Minimally Invasive Device TrabEx+ in Patients with Primary Open Angled Glaucoma

Purpose: The aim of our prospective study is to present the results of trabecular meshwork excision with the minimally invasive device TrabEx+ in patients with Primary Open-Angle Glaucoma (POAG). Methods: Patients diagnosed with POAG resistant to pharmacological treatment were included. All patients underwent as first non-medical treatment a trabecular meshwork excision with the use of TrabEx+. Results: 50 eyes of 50 patients with POAG (75.38±8.45 years, 21 males) were evaluated. The use of TrabEx+ resulted in a decrease of IOP the first postoperative day (by 11.2 mmHg) and remained decreased after one month (by 7.3 mmHg), three months (by 7.3 mmHg), six months (by 7.7 mmHg), one year (by 7.3 mmHg) and two years (by 6.7mmHg). Conclusion: The use of TrabEx+ is associated with a significant reduction in IOP pressure and medication and provides immediate and long-term effective results. TrabEx+ minimally invasive surgery is a safe and reliable alternative that could be added in the armamentarium of glaucoma management.